Correlation Between Eliem Therapeutics and Vaxcyte

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Vaxcyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Vaxcyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Vaxcyte, you can compare the effects of market volatilities on Eliem Therapeutics and Vaxcyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Vaxcyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Vaxcyte.

Diversification Opportunities for Eliem Therapeutics and Vaxcyte

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Eliem and Vaxcyte is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Vaxcyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaxcyte and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Vaxcyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaxcyte has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Vaxcyte go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Vaxcyte

Given the investment horizon of 90 days Eliem Therapeutics is expected to generate 1.01 times less return on investment than Vaxcyte. In addition to that, Eliem Therapeutics is 2.15 times more volatile than Vaxcyte. It trades about 0.03 of its total potential returns per unit of risk. Vaxcyte is currently generating about 0.07 per unit of volatility. If you would invest  5,025  in Vaxcyte on August 26, 2024 and sell it today you would earn a total of  3,829  from holding Vaxcyte or generate 76.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy99.7%
ValuesDaily Returns

Eliem Therapeutics  vs.  Vaxcyte

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Vaxcyte 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxcyte are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Vaxcyte showed solid returns over the last few months and may actually be approaching a breakup point.

Eliem Therapeutics and Vaxcyte Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and Vaxcyte

The main advantage of trading using opposite Eliem Therapeutics and Vaxcyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Vaxcyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcyte will offset losses from the drop in Vaxcyte's long position.
The idea behind Eliem Therapeutics and Vaxcyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance